Physician profile
Fonda Chan
NPI 1831446665
$33,247.85
in general payments reported to CMS, 2019-2025
68 companies · $6,173 in 2025
The $6,173 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,683 · 2020: $1,804 · 2021: $2,208 · 2022: $2,890 · 2023: $11K · 2024: $6,763 · 2025: $6,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,639 · Travel and Lodging: $1,490 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $8,639.24 |
| Travel and Lodging | $1,490.05 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $17,114.34 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $4,984.54 | 2019-2025 | |
| Ucb, INC. | $1,903.97 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Abbvie INC. | $1,265.63 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Eisai INC. | $555.81 | 2019-2025 | |
| Greenwich Biosciences, INC. | $493.54 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $454.28 | 2019-2024 | Daybue, Nuplazid |
| Novartis Pharmaceuticals Corporation | $341.52 | 2019-2025 | |
| Sk Life Science, INC. | $323.31 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $313.27 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $294.47 | 2019-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $260.57 | 2021-2025 | Ingrezza, Ongentys |
| Ipsen Biopharmaceuticals, INC | $254.49 | 2021-2024 | Dysport |
| Genentech USA, INC. | $235.21 | 2022-2023 | Ocrevus, Enspryng |
| Argenx US, INC. | $222.37 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fonda Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.